CTOs on the Move

Revibe Technologies

www.revibetech.com

 
Revibe Technologies is dedicated to helping children and adults overcome obstacles faced in the classroom and workplace by fusing psychology with technology. School psychologist Rich Brancaccio founded Revibe in 2013 to create a specialized tool to help kids overcome their difficulties by leveling the playing field through technology. Revibe is a wearable that leverages proprietary algorithms to help kids adults combat distraction through gentle vibration reminders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.revibetech.com
  • 3331 Heritage Trade Drive Suite 101
    Wake Forest, NC USA 27587
  • Phone: 919.521.8444

Executives

Name Title Contact Details
Christopher Guidry
Chief Technical Officer Profile

Similar Companies

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTL Biopharmaceuticals

XTL Biopharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIND Biosciences

BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PsychoGenics, Inc.

PsychoGenics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.